A detailed history of First Trust Advisors LP transactions in Revolution Medicines, Inc. stock. As of the latest transaction made, First Trust Advisors LP holds 155,189 shares of RVMD stock, worth $6.86 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
155,189
Previous 106,843 45.25%
Holding current value
$6.86 Million
Previous $4.15 Million 69.59%
% of portfolio
0.01%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$36.92 - $47.94 $1.78 Million - $2.32 Million
48,346 Added 45.25%
155,189 $7.03 Million
Q2 2024

Aug 13, 2024

BUY
$30.14 - $40.68 $3.22 Million - $4.35 Million
106,843 New
106,843 $4.15 Million
Q4 2023

Feb 13, 2024

SELL
$18.35 - $34.12 $449,281 - $835,394
-24,484 Reduced 28.46%
61,554 $1.77 Million
Q3 2023

Nov 13, 2023

BUY
$25.17 - $35.05 $2.17 Million - $3.02 Million
86,038 New
86,038 $2.38 Million
Q1 2023

May 15, 2023

SELL
$20.76 - $30.09 $1.49 Million - $2.16 Million
-71,831 Reduced 39.41%
110,414 $2.39 Million
Q4 2022

Feb 09, 2023

BUY
$17.68 - $25.53 $2.97 Million - $4.29 Million
167,859 Added 1166.82%
182,245 $4.34 Million
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $19,048 - $28,366
1,091 Added 8.21%
14,386 $284,000
Q2 2022

Aug 12, 2022

BUY
$14.54 - $27.17 $193,309 - $361,225
13,295 New
13,295 $259,000
Q3 2021

Nov 15, 2021

SELL
$23.95 - $33.41 $296,668 - $413,849
-12,387 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$29.0 - $47.44 $6.16 Million - $10.1 Million
-212,354 Reduced 94.49%
12,387 $393,000
Q1 2021

May 14, 2021

BUY
$37.21 - $54.43 $4.5 Million - $6.59 Million
121,023 Added 116.68%
224,741 $10.3 Million
Q4 2020

Feb 02, 2021

BUY
$30.19 - $45.49 $3.13 Million - $4.72 Million
103,718 New
103,718 $4.11 Million

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.88B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track First Trust Advisors LP Portfolio

Follow First Trust Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on First Trust Advisors LP with notifications on news.